BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.00
-0.82 (-1.39%)
Jul 11, 2025, 11:56 AM - Market open
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $745.15M in the quarter ending March 31, 2025, with 14.84% growth. This brings the company's revenue in the last twelve months to $2.95B, up 19.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$2.95B
Revenue Growth
+19.36%
P/S Ratio
3.80
Revenue / Employee
$970,469
Employees
3,040
Market Cap
11.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BMRN News
- 10 days ago - BioMarin Announces Completion of Acquisition of Inozyme - PRNewsWire
- 17 days ago - BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress - PRNewsWire
- 7 weeks ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire
- 2 months ago - BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma - PRNewsWire
- 2 months ago - BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PRNewsWire
- 2 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PRNewsWire
- 3 months ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire